Glaucoma Progressing Despite Normal Pressure: 24 Hour IOP

Glaucoma progression despite apparently controlled intraocular pressure is one of the most disorienting experiences a patient can face. It is also one of the most common reasons patients seek a glaucoma second opinion. The reason is almost always the same: daytime clinic readings capture one moment. They do not capture what happens at night, explains Dr Shibal Bhartiya.

Not all glaucoma medications lower pressure around the clock. Brimonidine and timolol both show significantly reduced activity after midnight. A patient whose pressure is controlled at 11 am may have entirely uncontrolled pressure at 3 am — and no standard clinic visit will reveal this.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.

My Glaucoma Is Progressing But My Pressure Is Always Normal. What Is Going On?

He was in his early sixties — careful, informed, and deeply confused.

He came to me for a second opinion after five to six years under glaucoma care. His file was meticulous. His lifestyle was exemplary — non-smoker, controlled blood pressure, controlled blood sugars. He was on two medications: timolol and brimonidine. His baseline IOP had been 26 to 27 mmHg. On treatment, it now sat at 13 to 14 mmHg at every clinic visit for years.

By every standard measure, he was a success story. But his glaucoma was still progressing.

He was not angry. He was bewildered. I have done everything right, he told me. Why is this still happening?

That question deserved a better answer than he had been given. The answer was in the hours nobody had measured.

The question nobody had asked

I looked at his records and asked him one thing: had anyone ever done a diurnal variation for him? A 24-hour IOP measurement, mapped across day and night? Or a Water Drinking Test?

He said no.

We enrolled him in a study using the Triggerfish sensor — a contact lens device that records continuous IOP fluctuation over 24 hours. The device does not measure absolute pressure values, but it maps the pattern of fluctuation with precision.

The night-time readings were almost double the daytime values.

Most clinic visits measure pressure once, mid-morning, when he was up and about. That is the reading least likely to catch a nocturnal spike. His reassuring numbers, always 13, always 14, had been capturing only half the story. The other half was unfolding while he slept, while no one was measuring, while his optic nerve absorbed damage that nobody anticipated.

Why his medications were failing him at night

The reason was pharmacological, and it is something worth stating clearly: brimonidine and timolol do not work at night. Their pressure-lowering effect drops sharply in the late hours. His reassuring clinic readings — always 13, always 14 — had been capturing only half the story. The other half was invisible, unfolding while he slept, while no one was measuring, while his optic nerve absorbed damage that nobody anticipated.

This is not a failure of the medications. It is a failure of the measurement system — and of the assumption that a daytime number tells the whole story.

What Doctors Often Miss

Brimonidine and timolol do not work at night. This is pharmacology, not failure — their pressure-lowering effect drops sharply in the late hours. It is a well-documented limitation that is not always communicated to patients or factored into treatment decisions.

The result is that a patient can have genuinely excellent daytime control and entirely uncontrolled nocturnal pressure simultaneously. Standard clinic visits — timed to office hours — will never detect this.

The other missed step is the diurnal variation test itself. It is one of the most underused and highest-yield investigations in glaucoma management. It is rarely ordered unless a specialist specifically suspects nocturnal IOP spikes. If your glaucoma is progressing despite apparently good readings, this investigation is worth asking for by name — and a glaucoma second opinion is always reasonable in this situation.


Why Prostaglandins Are First-Line for a Reason

We switched him to bimatoprost 0.01% — a prostaglandin analogue. Prostaglandins are the only class of glaucoma medication proven to work continuously across 24 hours. They do not lose activity at night.

That was in 2012 to 2013. He has been stable for over six years.

One molecule change. One question that had never been asked. Six years of stability that five years of treatment had never delivered.


Symptoms, Pressure Patterns, and When to Investigate

FindingLikely CauseWhen to Investigate Further
Glaucoma progressing despite good clinic IOPNocturnal IOP spike not captured by daytime readingsRequest 24-hour diurnal variation assessment
On timolol or brimonidine, still progressingNight-time loss of drug efficacyAsk whether a prostaglandin has been considered
Visual field deterioration at routine reviewOngoing IOP fluctuation between clinic visitsIOP fluctuation may be as damaging as sustained elevation
Good compliance, good lifestyle, still progressingMedication class mismatch for 24-hour coverageSecond opinion from glaucoma specialist
Pressure controlled but OCT showing RNFL thinningStructural damage continuing despite IOP numbersFull diurnal assessment and treatment review

What This Means for You

If your glaucoma is progressing despite readings that look controlled, the readings may be incomplete — not the whole story, only the morning chapter.

The questions worth asking at your next visit: Has my pressure ever been measured at night? Has anyone checked whether my medications work across 24 hours? Has a prostaglandin analogue been considered as my primary medication?

You are not doing anything wrong. The measurement system may simply be missing the hours that matter most.


If your glaucoma is progressing despite treatment, or if you have never had a 24-hour IOP assessment, a specialist review may give you answers years of routine care have not.

Book a consultation or second opinion with Dr Shibal Bhartiya in Gurgaon.
+91 88826 38735 | www.drshibalbhartiya.com


FAQs

My glaucoma is progressing but my eye pressure is always normal at the clinic. How is that possible?

Clinic readings capture pressure at one moment, usually mid-morning. Eye pressure fluctuates across 24 hours. Certain medications — including timolol and brimonidine — lose effectiveness at night. If pressure spikes at 2 am, no daytime clinic visit will catch it. That spike is still damaging your optic nerve, invisibly, visit after visit.

What is a diurnal variation test and do I need one?

A diurnal variation maps your eye pressure across the full day and night. It is recommended when glaucoma is progressing despite apparently controlled pressure, when you are on medications that may not provide round-the-clock coverage, or when your specialist suspects night-time IOP spikes. It is one of the most underused and highest-yield tests in glaucoma management.

Why are prostaglandin eye drops the first choice for glaucoma?

Prostaglandins are the only class of glaucoma medication that works continuously across 24 hours. Other drugs — including timolol and brimonidine — show significantly reduced activity at night. For long-term pressure control, the night-time hours matter as much as the daytime ones. This is why prostaglandin analogues are recommended as first-line therapy in international glaucoma guidelines.

Can glaucoma progress even when I am doing everything right?

Yes, and it is more common than patients realise. Controlled daytime pressure, healthy lifestyle, medication compliance — none of these guarantee protection if night-time IOP is unaddressed. Progression despite apparent control is a signal to investigate further, not to doubt yourself. A glaucoma second opinion is always reasonable in this situation.

Should I ask for a 24-hour IOP test if my glaucoma is progressing?

Yes. If your visual fields are declining despite good clinic readings, a diurnal variation assessment is a reasonable and important next step. Ask your glaucoma specialist specifically about this. It is a question worth asking at your next visit.


This page is part of the Advanced Glaucoma Care hub. Read about the full spectrum of glaucoma diagnosis and treatment. Please also read about Diurnal Variation of IOP, Target IOP and Glaucoma Eye Drops.

You may want to watch this podcast I did several years ago, for Health Talks.


Note: Contact Lens Monitor for Continuous IOP Monitoring

Triggerfish® contact lens sensor is a specialised diagnostic contact lens used in glaucoma care to monitor intraocular pressure (IOP)–related changes over 24 hours. Unlike routine pressure measurements taken during clinic hours, the Triggerfish lens (Sensimed Triggerfish) helps detect pressure fluctuations that may occur at night or outside OPD visits, which can sometimes explain progression despite apparently controlled readings. It does not measure pressure directly in mmHg but records circumferential corneal changes related to IOP patterns, helping glaucoma specialists better understand individual risk profiles and treatment needs in selected patients.

Dr Shibal Bhartiya was the first doctor in India to use the Triggerfish® contact lens sensor for Continuous IOP Monitoring in clinical practice. Her initial experiences on Intraocular pressure (IOP) related pattern in patients with primary angle closure (PAC) and primary angle closure glaucoma (PACG) before and after laser peripheral iridotomy (LPI) was presented at ARVO, in Orlando Florida in 2014

IOP Fluctuation and Angle Closure Glaucoma

IOP fluctuation is a particular concern in angle closure disease, where pressure spikes can be steep and are frequently missed by routine daytime readings. Dr Bhartiya’s published research has examined this directly. A 2015 study in the Journal of Current Glaucoma Practice, Diurnal Intraocular Pressure Fluctuation in Eyes with Angle-Closure (Bhartiya S, Ichhpujani P; PMID: 26997828), investigated IOP fluctuation across the day in 77 newly diagnosed angle closure patients and documented the range and pattern of diurnal variation in this group.

A 2019 review in the Romanian Journal of Ophthalmology, Diurnal Variation of IOP in Angle Closure Disease: Are We Doing Enough? (Bhartiya S et al.; PMID: 31687621), went further — finding that many clinical decisions in angle closure glaucoma management are based on only one or two IOP measurements, and arguing that this is insufficient given the established circadian rhythm of IOP and its direct correlation with glaucoma progression. Taken together, these papers make the case that angle closure patients may be among the most undertreated precisely because their worst pressure moments are the least observed.


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (PubMed-indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks, span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1,500+ Five Star Patient Reviews — Google Business Profile

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review. | www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Why Glaucoma Gets Worse Faster in Some People Than Others

Glaucoma can worsen faster in some people due to differences in optic nerve vulnerability, blood flow, and systemic risk factors, not just eye pressure. Even with “controlled” pressure, glaucoma may progress if underlying risks are not identified and monitored over time, Dr Shibal Bhartiya explains.

Two patients. Same diagnosis. Similar eye pressure. Same drops. One is stable at ten years. The other has lost significant field within three. Patients often ask: Why Glaucoma Gets Worse Faster in Some People Than Others.

This is not unusual in glaucoma. It is one of the most clinically important, and least explained, aspects of the disease. Your doctor told you, you have glaucoma, gave you drops. Called you back for monitoring.

But did you discuss if your optic nerve might be more vulnerable than average? Or, what factors beyond eye pressure are quietly accelerating the damage.

This article, written by Dr Bhartiya, explains those factors. Understanding them changes how glaucoma is monitored, what investigations are relevant, and what questions to ask at your next appointment.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.


Why Intraocular Pressure Is Only Part of the Story

The historical model of glaucoma was simple: raised intraocular pressure damages the optic nerve. Lower the pressure, stop the damage. This model is incomplete.

Intraocular pressure is the only modifiable risk factor with proven treatment benefit. It remains central to glaucoma management. But a substantial proportion of glaucoma patients, particularly those with normal tension glaucoma, progress despite pressure that is well controlled by any standard definition. And among patients with elevated pressure, some progress quickly while others with similar pressures remain stable for decades.

Pressure level explains some of the variation. The factors below explain the rest.


Central Corneal Thickness: The Hidden Pressure Modifier

Central corneal thickness (CCT) is one of the most important risk factors for glaucoma progression, and one of the most underappreciated by patients.

Intraocular pressure is measured by the resistance the cornea offers to an applanation probe or air puff. A thicker cornea gives artificially high readings. A thinner cornea gives artificially low ones. Standard Goldmann tonometry assumes a corneal thickness of approximately 545 microns. Patients with thinner corneas have their true pressure systematically underestimated at every clinic visit.

But CCT is not merely a measurement correction factor. Thin central cornea is an independent risk factor for glaucoma progression, separate from any pressure effect. The Ocular Hypertension Treatment Study (OHTS) identified CCT below 555 microns as one of the strongest predictors of conversion from ocular hypertension to glaucoma. Patients with thin corneas progress faster and reach endpoints earlier than those with normal or thick corneas, even after adjusting for measured IOP.

If you have glaucoma and have never had your corneal thickness measured, ask for it. It changes how your pressure readings should be interpreted, and it tells your specialist something important about your intrinsic risk.


Disc Haemorrhages: The Warning Signal That Gets Missed

A disc haemorrhage is a small, splinter-shaped bleed at the margin of the optic disc. It is visible on fundus examination and resolves within weeks to months. Most patients never know they have had one.

Disc haemorrhages are one of the strongest predictors of glaucoma progression. They indicate localised ischaemia, a transient interruption of blood flow, at the optic nerve head, and they mark the site of imminent or ongoing retinal nerve fibre layer loss. Studies consistently show that the sector of the optic nerve that bleeds is the sector that subsequently loses nerve fibres on OCT, and the sector where visual field loss subsequently develops.

In normal tension glaucoma, disc haemorrhages are particularly common and particularly significant. Their presence in an NTG patient is a direct signal that vascular insufficiency is active and that the nerve is under ischaemic stress beyond whatever pressure-related stress is present.

A patient whose disc haemorrhage is detected at a routine visit is not unlucky. The hemorrahe is a timely warning. The appropriate response is not to note it and move on. It is to ask why the bleed occurred, whether pressure targets need revision, and whether vascular risk factors need investigation.


Systemic Hypotension and Nocturnal Dipping

The optic nerve is supplied by blood from the posterior ciliary arteries. Like all tissues, it requires adequate perfusion pressure, the difference between arterial blood pressure and intraocular pressure, to receive oxygen and nutrients. When perfusion pressure falls, optic nerve gets less blood supply.

Systemic hypotension is a direct cause of reduced optic nerve perfusion pressure. It is most relevant at night. During sleep, blood pressure falls physiologically, this is normal nocturnal dipping. In some people, blood pressure dips excessively, by more than 20 percent from daytime levels. This is called nocturnal over-dipping.

Nocturnal over-dipping is strongly associated with glaucoma progression, particularly in normal tension glaucoma. The optic nerve, already under whatever pressure stress is present, faces additional ischaemic stress during the hours of maximum blood pressure reduction, precisely when patients are asleep and not being monitored.

The clinical implications are significant. Antihypertensive medications taken in the evening can exacerbate nocturnal dipping. A glaucoma patient who begins a new blood pressure medication and subsequently shows accelerated progression deserves a medication timing review. Taking antihypertensives in the morning rather than the evening, where clinically possible, may reduce nocturnal dipping and its consequences for the optic nerve.

A 24-hour ambulatory blood pressure monitor is a simple, non-invasive investigation that identifies nocturnal dipping. In standard glaucoma management, doctors forget about night time BP. In any patient with normal tension glaucoma or unexplained progression, however, it is essential.


Sleep Position: The Factor Nobody Mentions

The side on which a patient sleeps affects their intraocular pressure. This is documented, reproducible, and almost never discussed.

IOP is higher in the dependent eye, the eye facing down, when lying on one side. The mechanism involves increased episcleral venous pressure from the gravitational position. For a patient who sleeps consistently on one side, the dependent eye is exposed to elevated pressure for six to eight hours every night. Entirely outside the window of clinic measurement.

Studies using continuous IOP monitoring have shown that the dependent eye IOP during sleep can be 3 to 6 mmHg higher than the fellow eye. This is a clinically significant asymmetry in a disease. Especially where even 1 mmHg differences in pressure can result in measurable differences in progression rates.

This is relevant for any patient with asymmetric glaucoma, where one eye is worse than the other despite similar measured IOPs. If the worse eye is consistently the dependent eye, sleep position may be contributing.

Head-of-bed elevation, raising the head of the bed by 20 to 30 degrees, may reduce nocturnal IOP in both eyes. It is a simple, free, non-pharmacological intervention with evidence behind it.


Myopia: The Optic Nerve That Was Already Vulnerable

High myopia, short-sightedness above minus 3 to 5 dioptres, is an independent risk factor for glaucoma and for faster progression. The mechanism involves the structural anatomy of the myopic eye.

In a myopic eye, the scleral canal through which the optic nerve exits, the lamina cribrosa, is tilted, stretched, and biomechanically weaker than in an emmetropic eye. This altered geometry means the optic nerve is more susceptible to the same level of intraocular pressure that a normal eye would tolerate well. The lamina cribrosa in a myopic eye bends and deforms at lower pressure thresholds.

Myopic eyes also have thinner retinal nerve fibre layers at baseline: not from glaucoma, but from the axial elongation that stretches the retina. This makes OCT interpretation more complex: the baseline is lower, so the threshold for detecting abnormality shifts, and early glaucomatous loss can be masked within the range of normal myopic variation.

A highly myopic patient with glaucoma requires more conservative pressure targets, more careful OCT interpretation, and more frequent monitoring than a non-myopic patient with equivalent measured pressures.


Vascular Risk Factors: The Systemic Contributors

Glaucoma, particularly normal tension glaucoma, has a significant vascular component. The optic nerve depends on adequate, well-regulated blood flow. Conditions that impair vascular autoregulation or reduce perfusion contribute to nerve damage independently of intraocular pressure.

Migraine with aura is associated with glaucoma progression. The same cortical spreading depression and vasospasm that produces the migraine aura can affect the posterior ciliary circulation and cause episodic optic nerve ischaemia.

Raynaud’s phenomenon, episodic vasospasm of the extremities, is similarly associated with NTG. The vasospastic tendency that causes cold hands and feet also affects the microvasculature of the optic nerve.

Anaemia reduces oxygen delivery to the optic nerve and can accelerate progression in borderline cases. Obstructive sleep apnoea, covered in detail in a separate article, causes nocturnal hypoxia and IOP spikes that operate entirely outside clinical monitoring.

A complete glaucoma risk assessment includes a systemic vascular history. It is not sufficient to measure eye pressure, examine the disc, and send the patient home. The systemic picture matters.


What This Means for Your Monitoring

Understanding your personal risk profile changes what investigations are appropriate and what targets are realistic.

A patient with thin corneas, a history of disc haemorrhages, nocturnal dipping on antihypertensives, and high myopia has a fundamentally different risk profile from a patient with normal corneas, stable discs, well-controlled blood pressure, and no myopia: even if their measured IOPs are identical.

The first patient needs more aggressive pressure targets, more frequent OCT and field testing, 24-hour IOP monitoring consideration, an ambulatory blood pressure study, and a sleep apnoea screen. The second patient may be safely monitored annually with standard measurements.

If you have glaucoma and have never had a conversation about any of the factors above, you are not receiving complete care. A second opinion that includes a structured risk assessment, not just a pressure check, may change your management in ways that protect your vision for decades.


Clinical Reality (What’s not always obvious)

  • Progression in glaucoma is not equal across patients—two people with the same eye pressure can behave very differently over time.
  • “Controlled pressure” does not guarantee safety—factors like thin cornea, fragile optic nerve, or vascular instability can drive faster damage.
  • Systemic conditions (e.g., obstructive sleep apnea, low blood pressure at night, diabetes) can accelerate progression silently.
  • Missed doses, drop intolerance, or poor absorption reduce real-world protection even when prescriptions look adequate.
  • Progression is often only obvious in retrospect—which is why early, consistent follow-up matters more than occasional “good” visits.

What You Must Remember

FactorWhat It Means for You
Eye pressure levelHigher pressure → higher risk, but not the only driver
Optic nerve susceptibilitySome nerves are more vulnerable even at lower pressures
Corneal thicknessThin cornea can underestimate risk and true pressure
Type of glaucomaNormal tension vs high-pressure behave differently
Blood flow factorsPoor perfusion or fluctuations affect optic nerve health
Systemic conditionsSleep apnoea, diabetes, vascular disease increase risk
Medication adherenceIrregular use reduces protection significantly
Response to treatmentSome patients are non-responders to certain drops
Stage at diagnosisLate detection = faster apparent progression
Follow-up consistencyLong gaps → missed early warning signs
Big pictureGlaucoma progression is multi-factorial—pressure is just one piece of the puzzle

Frequently Asked Questions

Why is my glaucoma getting worse even though my eye pressure is controlled?

Intraocular pressure is one of several factors driving glaucoma progression. Thin corneas, disc haemorrhages, nocturnal blood pressure dipping, sleep position, myopia, and vascular conditions can all accelerate damage independently of measured IOP. A structured risk assessment should investigate these factors in any patient with unexplained progression.

What is a disc haemorrhage and should I be worried?

A disc haemorrhage is a small bleed at the optic disc margin. It is one of the strongest predictors of glaucoma progression and indicates localised ischaemia at the nerve head. If one is detected, it should prompt a review of pressure targets, vascular risk factors, and monitoring frequency, not simply be noted and observed.

Does blood pressure affect glaucoma?

Yes, significantly. Low blood pressure, particularly nocturnal over-dipping, reduces optic nerve perfusion pressure and accelerates glaucomatous damage. Evening antihypertensive medications can exacerbate nocturnal dipping. A 24-hour ambulatory blood pressure monitor identifies this pattern and can guide medication timing.

Does sleep position affect eye pressure?

Yes. The dependent eye in a side-sleeping patient has measurably higher IOP than the fellow eye, due to increased episcleral venous pressure. In patients with asymmetric glaucoma, sleep position may be a contributing factor. Head-of-bed elevation reduces nocturnal IOP in both eyes.

Does myopia make glaucoma worse?

High myopia makes the optic nerve more vulnerable to glaucomatous damage at any given pressure. The lamina cribrosa in a myopic eye is structurally weaker and deforms at lower pressure thresholds. Myopic patients with glaucoma require more conservative targets and more careful monitoring.

What is central corneal thickness and why does it matter?

Central corneal thickness affects the accuracy of IOP measurement and is an independent risk factor for glaucoma progression. Thin corneas lead to underestimation of true IOP and carry intrinsically higher progression risk. Every glaucoma patient should have their corneal thickness measured and their pressure readings interpreted in that context.


Read the research articles.

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine,.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

Access her work on PubmedGoogle ScholarResearchGate and ORCID.

Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care

www.drshibalbhartiya.com
 +91 88826 38735

1500+ Five Star Patient Reviews Google Business Profile

Upload your reports for a structured review.

How to Reduce Glaucoma Eye Drops

You can reduce glaucoma eye drops safely under medical supervision, BUT only when your eye pressure is consistently controlled and your optic nerve shows no ongoing damage. Laser therapy, minimally invasive surgery, and fixed-dose combination drops are the main routes your glaucoma specialist will consider, says Dr Shibal Bhartiya. Moreover, your target IOP must be achieved even without your eye drops. Remember, your eye pressure is normal, and your optic nerve is safe BECAUSE OF THE EYE DROPS.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialistand Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damageis irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.

Clinical Reality (What’s not always obvious)

“Fewer drops” is only meaningful if the long-term risk of vision loss remains controlled.Why Number of Drops Matters

Reducing drops is not a shortcut—it’s a risk decision based on optic nerve stability, not just a “good” pressure reading.

Some patients appear stable short-term but show progression over time—this is why reduction is usually trialled and monitored, not assumed safe.

Side effects (redness, dryness, surface toxicity) are valid reasons to simplify—but need structured alternatives, not abrupt stopping.

Options like laser (SLT) or combination drops may reduce drop burden without reducing protection.

Every additional drop raises the risk ofside effects, surface toxicity, and poor adherence. Patients on three or more drops have significantly lower adherence rates. Lower adherence means higher risk of disease progression. Reducing drops is not about convenience only. It is about protecting your vision more effectively.

When Can Drops Be Reduced?

Your doctor will consider reducing drops when:

Reduction is never automatic. It requires a clinical decision based on your individual risk profile.

And then, your doctor will continue to check your eye pressure, to make sure your target IOP is achieved with fewer drops, laser, or surgery. If it is not, your doctor will restart the drops that were stopped.

How Drops Are Reduced

1. Selective Laser Trabeculoplasty (SLT)

SLT is now considered a first-line treatment for glaucoma in many patients. It reduces IOP effectively in over 70% of patients. Many patients can reduce or stop drops entirely after SLT. The effect lasts three to five years and the procedure can be repeated.

2. Fixed-Dose Combination Drops

Two medicines in one bottle replace two separate bottles. You reduce the number of drops without reducing medication. This also reduces preservative exposure, which damages the ocular surface over time.

3. Minimally Invasive Glaucoma Surgery (MIGS)

MIGS procedures improve fluid drainage from the eye. They reduce drop dependency significantly in suitable patients. They carry a lower risk profile than traditional glaucoma surgery. MIGS is often combined with cataract surgery for maximum benefit.

4. Trabeculectomy or Glaucoma Drainage Devices

In advanced glaucoma with poor IOP control, surgery may be the most reliable way to eliminate drops. Trabeculectomy remains the gold standard for sustained IOP reduction. Drainage devices offer an alternative in complex cases.

Can You Stop Drops on Your Own?

No. Stopping glaucoma drops without medical guidance causes IOP to rise, often without symptoms. Glaucoma causes permanent, irreversible vision loss. Never reduce or stop drops without your specialist’s explicit advice.

What to Discuss with Your Doctor

Ask about your target IOP and whether you are meeting it. You must ask whether SLT is an option for you. Ask whether your current combination of drops can be simplified. Ask about your progression risk and whether surgery would offer better long-term control.

Known for her structured approachto glaucoma risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinionsfor patients seeking clarity before major treatment decisions. Both, in person, and online.

The Bottom Line

Fewer drops can mean better adherence, a healthier ocular surface- but only if there is equally good or better, IOP control.The goal is always to protect your optic nerve with the simplest regimen that achieves your target pressure. Talk to a glaucoma specialist before making any changes.


What You Must Remember

AspectWhat It Means for You
GoalReduce medication burden without increasing risk from glaucoma
Who may be eligibleStable patients with consistent tests over time
When not to reduceProgressive disease, high-risk optic nerve, unreliable follow-up
How reduction is doneStepwise, one change at a time, with close monitoring
Role of SLT (laser)Can reduce or replace drops in selected patients
Combination dropsFewer bottles, same or better pressure control
What is monitoredEye pressure, OCT (structure), visual fields (function)
Time frameNeeds follow-up over months—not a one-visit decision
RisksSilent progression if reduced too early or without monitoring
Big pictureThe safest plan is not the least treatment—it’s the right amount of treatment over time

FAQs

Can I reduce my glaucoma drops if my pressure is normal?

Stable eye pressure is one factor, but your doctor also needs to confirm that your optic nerve and visual fields show no ongoing damage before considering any reduction.

Is laser treatment a permanent replacement for drops?

SLT is effective for three to five years in most patients and can be repeated. It reduces or eliminates drop need in many cases, but it is not permanent for everyone.

What happens if I stop glaucoma drops suddenly?

IOP rises, often without any symptoms. Glaucoma damage is silent and irreversible. Never stop drops without guidance from your glaucoma specialist.

Are combination drops as effective as separate drops?

Yes. Fixed-dose combinations deliver the same medicines with fewer bottles, fewer daily instillations, and less preservative exposure to the eye surface.

Read the research articles

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

Access her work on PubmedGoogle ScholarResearchGate and ORCID.

Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care

www.drshibalbhartiya.com
 +91 88826 38735

1500+ Five Star Patient Reviews Google Business Profile

Upload your reports for a structured review.

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation for glaucoma

Online Glaucoma Consultation with Dr Shibal Bhartiya

Online Glaucoma Consultation with Dr Shibal Bhartiya | Teleconsult from Anywhere in India. You do not need to travel to get expert glaucoma advice. Dr Shibal Bhartiya offers secure online glaucoma consultations for patients across India and internationally. Whether you want a second opinion on a recent diagnosis, guidance on whether your current treatment is working, or expert review of your reports before planning surgery, you can access specialist care from your home.

Glaucoma is a silent disease. It causes no pain. It takes vision gradually. By the time most patients feel something is wrong, significant damage has already occurred. This makes expert, timely advice critical, wherever you live.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.


What Is an Online Glaucoma Consultation?

An online consultation is a video or written appointment with Dr Shibal Bhartiya conducted through a secure digital platform.

You share your reports, scans, and history in advance. Dr Bhartiya reviews them in detail. During your appointment, she explains what your test results mean, answers your questions, and gives you a clear plan.

You leave knowing exactly where you stand.

Upload your reports for a structured, independent glaucoma second opinion.


Who Should Book an Online Glaucoma Consultation?

You have been recently diagnosed with glaucoma

A new glaucoma diagnosis raises many questions. Is the damage serious? Do you need drops immediately? Is surgery being recommended too soon? An expert second opinion helps you make informed decisions without delay.

Your glaucoma is progressing despite treatment

If your visual fields or OCT scans show progression even while on drops, something needs to change. Dr Bhartiya reviews your full clinical picture and identifies whether treatment requires adjustment.

You want a second opinion before glaucoma surgery

Surgery for glaucoma is not always urgent. In some cases it is the right decision early. In others, better medical management can delay or avoid it. A specialist review before any procedure gives you clarity and confidence.

You live outside Gurugram or outside India

Patients from smaller cities, towns, and Indian communities abroad frequently consult Dr Bhartiya online. You receive the same standard of care as an in-person patient at Marengo Asia Hospitals.

Your family member has glaucoma and you want to know your own risk

Glaucoma has a strong genetic component. First-degree relatives of glaucoma patients face a significantly higher lifetime risk. An online consultation can help you understand your risk, what to watch for, and when to start screening.

You are confused by conflicting advice from different doctors

Multiple opinions with different recommendations can be disorienting. Dr Bhartiya reviews your full record and gives you a single, clear clinical perspective backed by evidence and experience.


What to Share Before Your Appointment

Bring the following to your online consultation:

You do not need all of these. Share what you have. Dr Bhartiya works with whatever clinical information is available.


What Happens During the Consultation?

The appointment typically runs 20 to 30 minutes.

The teleconsult begins with a structured review of your reports. Dr Bhartiya explains what each result means in plain language. She then identifies where damage has occurred, how fast it is progressing, and whether your current treatment is adequate.

She then answers your questions directly. No deflection. No vague reassurance. You receive honest, evidence-based guidance on your specific situation.

After the consultation, a written summary is shared with you. This includes Dr Bhartiya’s clinical impression, recommendations, and any suggested next steps.


Conditions Covered in Online Glaucoma Consultations

Dr Bhartiya offers teleconsultation for the following:


Why Patients Choose Dr Shibal Bhartiya for Online Glaucoma Consultations

Dr Bhartiya brings over 25 years of clinical experience in glaucoma. Her training spans AIIMS New Delhi, the University of Geneva, and an ongoing research collaboration with Mayo Clinic. She has authored 28 textbooks and published more than 200 peer-reviewed papers, 90+ indexed on Pubmed. Dr Bhartiya also serves as Executive Editor of the Journal of Current Glaucoma Practice.

She is not a general ophthalmologist who also sees glaucoma. Glaucoma is her entire clinical focus.

Patients who consult her online frequently report that their diagnosis became clearer in a single appointment than it had been over months of follow-up elsewhere. Not because their previous doctors were wrong, but because specialist interpretation of glaucoma investigations requires a specific depth of experience.


How to Book Your Online Glaucoma Consultation

Booking takes two minutes.

Call or WhatsApp: +91 88826 38735 Email: Through the contact form on this website Platform: Google Meet, Zoom, or WhatsApp Video, whichever is easiest for you

Once you confirm your appointment, share your reports by WhatsApp or email at least 24 hours before your scheduled time. Dr Bhartiya reviews them before you speak.


FAQs about Teleconsults

Can I consult Dr Bhartiya online if I live outside India?

Yes. Dr Bhartiya consults patients across India and internationally. She sees patients from the Middle East, the UK, the United States, Canada, and Southeast Asia regularly. The appointment is conducted in English or Hindi.

Is an online glaucoma consultation as useful as an in-person visit?

For most clinical questions, yes. Report interpretation, treatment review, second opinion, pre-surgical evaluation, and medication guidance can all be done effectively online. Patients who need imaging or a physical examination are advised to visit in person, with clear guidance on what tests to get locally first.

How do I share my glaucoma reports for the consultation?

Send your scanned reports or photos of your printed reports by WhatsApp to +91 88826 38735 or by email. PDF format is preferred. You can also photograph documents clearly on a flat surface if you do not have digital copies.

Will I receive a written summary after the consultation?

Yes. A written clinical summary is provided after every consultation. This includes Dr Bhartiya’s findings, recommendations, and suggested next steps. You can share this with your treating ophthalmologist. Dr Bhartiya is also happy to discuss your case with your treating eye doctor.

What is the fee for an online consultation?

Please contact the clinic directly for current consultation fees. Fees vary depending on the nature and complexity of the consultation. Dr Bhartiya also offers her services pro bono, and allows you the option of donating to her not-for-profit, Vision Unlimited which works with children in the urban slums of Gurgaon.

Can Dr Bhartiya prescribe medication during an online consultation?

Dr Bhartiya provides clinical guidance and recommendations. Formal prescription issuance follows applicable telemedicine regulations in India. She will advise you clearly on what to do next and how to work with your local doctor if a formal prescription is required outside the country.

How soon can I get an appointment?

Most patients get an appointment within 2 to 5 working days. Urgent consultations are accommodated where possible. Contact the clinic directly to check availability.


Glaucoma does not wait. Neither should you.

If you have reports sitting on your phone that no one has explained clearly, if your treatment feels uncertain, if you have been told you need surgery and want to be sure, this is the consultation that brings clarity.

Read the research articles

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. This article was edited in April 2026.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

Her work can be accessed on PubmedGoogle ScholarResearchGate and ORCID.

Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care

www.drshibalbhartiya.com
 +91 88826 38735

1500+ Five Star Patient Reviews Google Business Profile

Upload your reports for a structured review.

Why Do I Need So Many Glaucoma Eye Drops?

Needing multiple glaucoma eye drops usually means your eye pressure is not adequately controlled with a single medication. Each drop…